7 years ago

Dysis Medical Secures £18 Million to Expand Cervical Cancer Screening Technology

  • Dysis Medical, a Scottish developer of a colposcope for cervical cancer screening, has secured £18 million in funding from Lundbeckfonden Ventures

  • This investment will support expansion in the US, UK, and other key markets, as well as advancements in strategic R&D programs

  • Dysis Medical's technology utilizes patented optical and software techniques to scan a patient's cervix, quantify the results, and present them to a clinician in a color-coded map

  • The company has recently launched its latest device, DYSIS Ultra, and published updated guidance recommending its adoption by the NHS, along with US clinical data.

      • ProblemHealthcare

      "Current cervical cancer screening methods are time-consuming, subjective, and often inaccurate, leading to unnecessary biopsies and missed diagnoses."

      Solution

      "DYSIS Medical has developed a revolutionary colposcope that uses patented optical and software techniques to scan a patient’s cervix, quantify the results, and present them to a clinician in the form of an intuitive colour-coded map. This technology improves the accuracy and efficiency of cervical cancer screening, reducing the need for unnecessary biopsies and improving patient outcomes."

      Covered on